KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Free Cash Flow: 2010-2025

Historic Free Cash Flow for Nektar Therapeutics (NKTR) over the last 16 years, with Sep 2025 value amounting to -$48.9 million.

  • Nektar Therapeutics' Free Cash Flow fell 9.59% to -$48.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$190.4 million, marking a year-over-year decrease of 7.05%. This contributed to the annual value of -$177.2 million for FY2024, which is 8.42% up from last year.
  • According to the latest figures from Q3 2025, Nektar Therapeutics' Free Cash Flow is -$48.9 million, which was down 6.77% from -$45.8 million recorded in Q2 2025.
  • Over the past 5 years, Nektar Therapeutics' Free Cash Flow peaked at -$37.9 million during Q2 2024, and registered a low of -$157.4 million during Q4 2021.
  • In the last 3 years, Nektar Therapeutics' Free Cash Flow had a median value of -$47.3 million in 2023 and averaged -$46.8 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first tumbled by 90.66% in 2021, then spiked by 63.02% in 2022.
  • Nektar Therapeutics' Free Cash Flow (Quarterly) stood at -$157.4 million in 2021, then spiked by 63.02% to -$58.2 million in 2022, then grew by 18.78% to -$47.3 million in 2023, then rose by 1.35% to -$46.6 million in 2024, then decreased by 9.59% to -$48.9 million in 2025.
  • Its last three reported values are -$48.9 million in Q3 2025, -$45.8 million for Q2 2025, and -$49.1 million during Q1 2025.